Clinical Trial VICCNEU1268


Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers

Principal Investigator(s)

Chad Quarles


  • Protocol No. VICCNEU1268
  • Open Date: 05/01/2012
  • Staging: NA
  • Age Group: Adults
  • Scope: Local
  • Objective: To determine the potential of MRI-based biomarkers, specifically those sensitive to tumor blood flow, protein content and cellularity, to accurately determine the response of patients with Stage III/IV glioma to radiation therapy combined with chemotherapy or bevacizumab.
  • Disease Sites: Neuro-Oncology
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01996527
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.